On July 15, 2021, Wugen, Inc., a clinical-stage biotechnology company, announced the completion of an oversubscribed $172 million Series B financing led by Abingworth and Tybourne Capital Management. Wilson Sonsini Goodrich & Rosati represented Tybourne Capital on the related corporate and intellectual property matters.

According to the press release, proceeds from the financing will support further clinical development of Wugen’s best-in-class memory natural killer cell platform and advance ongoing trials for patients with severe acute myelogenous leukemia and other oncology indications, including solid tumors. The company also plans to use the proceeds to advance its broader pipeline of next-generation products into the clinic.

The Wilson Sonsini team advising Tybourne Capital includes the following attorneys:

Corporate
Dan Koeppen, Partner
Meghan Burton, Associate

Intellectual Property
Maya Skubatch, Partner
Matt Wheeler, Associate
Minyoung Shin, Associate

Please see the press release announcing the financing for more information.